Evidence Hub

Comparing Appetite and Dietary Intake Responses to Resistance Exercise in Breast Cancer Survivors Undergoing Adjuvant Endocrine Therapy Versus Individuals Without Cancer: A Secondary Analysis

Purcell SA, Halliday TM, Melanson EL, Afghahi A, Borges VF, Sinelli I, Cornier MA

Nutrition and cancer, 2025

Abstract

Breast cancer survivors (BCS) undergoing adjuvant endocrine therapy have increased risk of obesity. Estrogen and exercise suppress appetite in non-BCS populations, but their combined effects in BCS are unknown. This secondary analysis compared the impact of acute resistance exercise (REx) on appetite and energy intake in estrogen-suppressed BCS versus females without cancer ('non-BCS'). Premenopausal inactive BCS (stage 0-III estrogen receptor-positive breast cancer, 2) and 12 non-BCS (age: 37 ± 8; BMI: 29.0 ± 5.1 kg/m2) were included. BCS showed greater PYY 90 and 120 min post-breakfast compared to non-BCS, particularly after REx (group x time x condition: p = 0.009, p = 0.005, respectively). No group effects were observed for ghrelin. BCS had lower body mass-adjusted energy intake compared to non-BCS (p = 0.036), despite similar appetite ratings. Estrogen-suppressed BCS exhibit heightened PYY and lower energy intake after REx, revealing novel effects of exercise on appetite in a state of low estrogen.

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free